ArticleMolecular cell2019
N6-Methyladenosine Modification Controls Circular RNA Immunity.
Open access · bronzeAbstract readComparative Study
In one paragraph
Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 395 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
395citing papers in PubMed, 1 pooled it
27.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
395 citing papers in PubMed, 1 synthesis or guideline pooled it, 564 citations in OpenAlex.
- Current situation and trend of non-coding RNA in rheumatoid arthritis: a review and bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Non-coding RNAs in dermatophytosis: Key regulators of host-fungal interactions and pathogenesis-A review.Virulence · 2026Review
- Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review).International journal of molecular medicine · 2026Review
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.Vaccines · 2026Review
- Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Split intron-exon system for circular RNA synthesis.Nature communications · 2026Article
- IVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- The emerging role of circular RNAs in neurodegenerative diseases and viral infections.Journal of neurovirology · 2026Review
- Review
- Review
- Ubiquitination and NOncology letters · 2026Review
- Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.Nature biomedical engineering · 2026Article
- Neuronal YTHDF2 suppresses innate immune activation in Aβ pathology by promoting mScience advances · 2026Article
- CircRNA-regulated programmed cell death networks in cardiomyocytes: Molecular crosstalk and therapeutic translation.Non-coding RNA research · 2026Review
- Synthetic circRNAs employ IRES activity for translation in cells and in cell-free translation systems.bioRxiv : the preprint server for biology · 2026Article
- The epitranscriptomic m6A RNA modification modulates the synapse in ageing and in a mouse model of synucleinopathy.NPJ Parkinson's disease · 2026Article
- Site-Specifically Modified Circular Ribonucleic Acid Serves as Multitarget miRNA Sponge with Low Immunogenicity.Journal of the American Chemical Society · 2026Article
- The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives.Molecular cancer · 2026Review
335 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 1 country.
Y Grace ChenCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA 94305, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06519, USA.
Robert ChenCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA 94305, USA.
Sadeem AhmadDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Rohit VermaInstitute for Immunity, Transplantation and Infection, Department of Pathology, Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
Sudhir Pai KasturiEmory Vaccine Center/Yerkes National Primate Research Center at Emory University, Atlanta, GA, USA.
Laura AmayaCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA 94305, USA.
James P BroughtonCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA 94305, USA.
Jeewon KimStanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Cristhian CadenaDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Bali PulendranInstitute for Immunity, Transplantation and Infection, Department of Pathology, Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
Sun HurDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA. Electronic address: howchang@stanford.edu.
Stanford University · USBoston Children's Hospital · USEmory University · USHarvard University · USHoward Hughes Medical Institute · USYale University · US
Funding
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7MTranslational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4MLncRNA mechanisms in cancerR35CA209919 · NCI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2016 to 2022
$6.4MYALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1MGraduate Training Program in BiotechnologyT32GM008412 · NIGMS · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 1991 to 2020
$5.5MStructural and functional analyses of the RIG-I filament in innate immunityR01AI111784 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUR, SUN · 2014 to 2023
$4.9MStructural Motifs in RNAR01HG004361 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2007 to 2018
$4.7MUnderstanding the Role of Mucosal Antigen Presenting Cells in Regulating Immune ResponseR37AI048638 · NIAID · STANFORD UNIVERSITY · PI PULENDRAN, BALI · 2009 to 2018
$4.0MPolarizing T Cell Responses in vivo With Dendritic CellsR37DK057665 · NIDDK · STANFORD UNIVERSITY · PI PULENDRAN, BALI · 2010 to 2019
$3.9MMolecular Mechanisms for Antiviral Signal Activation by MDA5 and RIG-IR01AI106912 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUR, SUN · 2014 to 2018
$2.2MBD Canto II RUO CytometerS10RR027431 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$236kNCI NIH HHS K12 CA215110NCI NIH HHS P30 CA124435NCI NIH HHS R35 CA209919NCRR NIH HHS S10 RR027431NHGRI NIH HHS R01 HG004361NIAID NIH HHS R01 AI106912NIAID NIH HHS R01 AI111784NIAID NIH HHS R37 AI048638NIAID NIH HHS U19 AI057266NIDDK NIH HHS R37 DK057665NIGMS NIH HHS T32 GM008412
Abstract
Circular RNAs (circRNAs) are prevalent in eukaryotic cells and viral genomes. Mammalian cells possess innate immunity to detect foreign circRNAs, but the molecular basis of self versus foreign identity in circRNA immunity is unknown. Here, we show that N6-methyladenosine (m
Indexed as
Immunity, InnateAdaptor Proteins, Signal TransducingAdenosineAdjuvants, ImmunologicAnimalsCD8-Positive T-LymphocytesDEAD Box Protein 58FemaleHEK293 CellsHeLa CellsHumansImmunizationInterferon Regulatory Factor-3InterferonsLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalAdaptor Proteins, Signal TransducingAdenosineAdjuvants, ImmunologicDdx58 protein, mouseDEAD Box Protein 58Interferon Regulatory Factor-3InterferonsIRF3 protein, humanMAVS protein, humanN-methyladenosinePolyubiquitinReceptors, ImmunologicRIGI protein, humanRNA-Binding ProteinsRNA, CircularYTHDF2 protein, humancancer immunotherapycircular RNAN6-methyladenosineRIG-Iself/non-selfvaccineYTHDF
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.